01—Abstract
Summary
Summary of the 8-K filed August 5, 2026. Cited figures are marked; the original filing is the authoritative source.
Exelixis, Inc. reported financial results for the second quarter ended June 30, 2026 (the filing's fiscal quarter ended July 3, 2026) in a press release furnished as Exhibit 99.1 to this Form 8-K.
Total revenues were $628.7 milliona, up from $568.3 million a year earlier, driven by net product revenues of $573.0 million (versus $520.0 million), which the company attributed primarily to higher sales volume. GAAP net income was $212.1 million, or $0.82 per diluted share, compared with $184.8 million, or $0.65 per diluted share, in the prior-year quarter. Non-GAAP net income was $237.1 million, or $0.91 per diluted share.
Research and development expenses rose to $212.0 million and SG&A expenses rose to $147.6 millionb. Exelixis lowered its FY 2026 guidance. Total revenues are now expected at $2.500 billion to $2.550 billion (previously $2.525 billion to $2.625 billion), net product revenues at $2.300 billion to $2.350 billion (previously $2.325 billion to $2.425 billion), and R&D expenses at $825 million to $875 million (previously $875 million to $925 million).
Guidance excludes any revenue from a potential launch of zanzalintinib in metastatic colorectal cancer. The FDA is reviewing the zanzalintinib NDA, with a PDUFA target action date of December 3, 2026.
The company repurchased $311.6 millionc of stock in the quarter at an average price of $47.85 per share, completed the $750 million October 2025 repurchase program, and began executing a new $750 million program authorized in May 2026 that runs through December 31, 2027. The filing also outlines pipeline milestones, including topline STELLAR-304 results expected in the second half of 2026 and initiation of the STELLAR-316 pivotal trial in mid-2026.
02—Key points
Key Highlights
- Total revenues of $628.7 million for Q2 2026, up from $568.3 million in Q2 2025; net product revenues were $573.0 million versus $520.0 million.
- GAAP diluted EPS of $0.82 versus $0.65 a year earlier; non-GAAP diluted EPS of $0.91 versus $0.75.
- FY 2026 guidance lowered: total revenues $2.500–$2.550 billion (from $2.525–$2.625 billion) and net product revenues $2.300–$2.350 billion (from $2.325–$2.425 billion); R&D expense guidance reduced to $825–$875 million.
- Zanzalintinib NDA for metastatic CRC (with atezolizumab) is under FDA review with a PDUFA target action date of December 3, 2026; guidance excludes any launch revenue.
- Repurchased $311.6 million of stock in Q2 at an average price of $47.85 per share and completed the $750 million October 2025 program; a new $750 million program authorized in May 2026 runs through December 31, 2027.
- Phase 3 STELLAR-304 topline results expected in the second half of 2026; STELLAR-316 pivotal trial expected to start in mid-2026.
- Cabozantinib franchise U.S. net product revenues were $573.0 million in Q2, with Exelixis earning $53.2 million in royalty revenues from partner sales.
03—Questions
Frequently Asked Questions
Why did Exelixis lower its 2026 revenue guidance?
The filing shows that total revenue guidance moved from $2.525–$2.625 billion to $2.500–$2.550 billion, and net product revenue guidance moved from $2.325–$2.425 billion to $2.300–$2.350 billion. The filing does not state a specific reason for the change, though it notes that guidance does not reflect any revenue from a potential zanzalintinib launch.
What is the key regulatory catalyst for zanzalintinib?
The FDA is reviewing the NDA for zanzalintinib in combination with atezolizumab for previously treated metastatic colorectal cancer, with a PDUFA target action date of December 3, 2026. The company said the launch is pending approval from regulatory authorities later this year.
How much stock has Exelixis repurchased and what remains authorized?
In Q2 2026 Exelixis repurchased $311.6 million of stock at an average price of $47.85 per share and completed the $750 million October 2025 program. The May 2026 program authorizes up to an additional $750 million before December 31, 2027, and repurchase execution under it began in Q2 2026. Since March 2023, the company has repurchased a total of $2.9 billion, retiring 93.3 million shares.
Why did GAAP EPS rise faster than net income?
The filing states that GAAP net income per share was favorably impacted by lower weighted-average common shares outstanding, which resulted from the stock repurchase programs. Diluted weighted-average shares were 259.7 million in Q2 2026 versus 284.4 million in Q2 2025.
What clinical readouts are expected next?
Exelixis expects topline results from the phase 3 STELLAR-304 trial (zanzalintinib plus nivolumab in non-clear cell renal cell carcinoma) in the second half of 2026, depending on event rates. It also expects to initiate the phase 3 STELLAR-316 pivotal trial in mid-2026 and the phase 2 STELLAR-202 trial in the second half of 2026.
04—Continue